Trevi Therapeutics, Inc.
(TRVI - NASDAQ)
14,27 USD
📋 Profilo Aziendale

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions.

|